Role of Zolpidem in the Management of Insomnia
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Insomnia is a common condition that affects one's ability to sleep comfortably and consequently to work effectively. Its etiology is multifactorial and involves plethora of risk factors. Consequences can vary from mild sleepiness to more sever psychiatric disturbances and ischemic stroke. Despite several diagnostic criteria it is poorly diagnosed and less often treated. Benzodiazepines formed the mainline therapy for many years till the advent of newer nonbenzodiazepine group of drugs including zolpidem. Zolpidem is an imidazo‐pyridine compound that enhances the GABA A receptor function by interaction with Omega‐1 receptor subtype. Its pharmacokinetic profile allows the patients to use it later in the night when having trouble falling asleep without any residual cognitive impairment the next morning. It has rapid onset of action, improves total sleep duration, and reduces night‐time awakenings. Its adverse effect profile is satisfactory as it appears to have low addiction potential. This review will focus on the current role of zolpidem in the management of insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of insomnia: what we know and what we still need to learn
Ohayon, M. M. (2002) · Sleep Medicine Reviews · doi:10.1053/smrv.2002.0186 · Cited by 3,743 · cited 1×
“More than onethird of adults report some degree of insomnia within any given year, and 2 to 6% use medications to aid sleep [3].”
BackgroundAssociation of sleep time with diabetes mellitus and impaired glucose tolerance
Gottlieb, D. J., Punjabi, N. M., Newman, A. B., Resnick, H. E., Redline, S., Baldwin, C. M., & Nieto, F. J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.863 · Cited by 927
Publication bias in clinical trials due to statistical significance or direction of trial results
Hopewell, S., Loudon, K., Clarke, M. J., Oxman, A. D., & Dickersin, K. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000006.pub3 · Cited by 898 · cited 1×
“, who assessed the extent to which publication of a cohort of clinical trials is influenced by the statistical significance, perceived importance, or direction of their results [92].”
BackgroundPlace of chronic insomnia in the course of depressive and anxiety disorders
Ohayon, M. M., & Roth, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00052-3 · Cited by 873 · cited 1×
“Insomnia is a distressing condition that affects not only the ability to sleep adequately at night, but also to function effectively during one’s desired waking time [1].”
BackgroundNational Institutes of Health State of the Science Conference Statement
(2005) · Sleep · doi:10.1093/sleep/28.9.1049 · Cited by 745
Sleep and depression--results from psychobiological studies: an overview
Riemann, D., Berger, M., & Voderholzer, U. (2001) · Biological Psychology · doi:10.1016/s0301-0511(01)00090-4 · Cited by 653
Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451 · cited 1×
“in which they evaluated the efficacy of benzodiazepines and zolpidem tartrate in all the randomized, double-blind, placebo-controlled, parallel or crossover designs with benzodiazepines or zolpidem in adults younger than 65 years with chronic insomnia, they found out that benzodiazepines and zolpidem produced reliable…”
BackgroundHajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317 · cited 1×
“Zolpidem is primarily effective in inducing sleep with minimal effect on sleep duration or sleep maintenance [27].”
BackgroundEffects of rapid versus slow accumulation of eight hours of sleep loss
Drake, C. L., Roehrs, T. A., Burduvali, E., Bonahoom, A., Rosekind, M., & Roth, T. (2001) · Psychophysiology · doi:10.1111/1469-8986.3860979 · Cited by 231
Cited by
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230
“Currently, there are three Food and Drug Administration (FDA)-approved, commercially available, non-benzodiazepine drugs in the USA for the treatment of insomnia: zaleplon, zolpidem, and eszopi-clone (the active enantiomer of zopiclone) [5].”
In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0294-y · Cited by 177
Messineo, L., Eckert, D. J., Lim, R., Chiang, A., Azarbarzin, A., Carter, S. G., & Carberry, J. C. (2020) · The Journal of Physiology · doi:10.1113/jp280173 · Cited by 71
“It is widely prescribed to decrease sleep onset latency and acutely manage insomnia (Dang et al. 2011).”
Background
Metadata
- Authors
- Dang, A., Garg, A., & Rataboli, P. V.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2011-09-23
- Volume
- 17
- Issue
- 5
- Pages
- 387-397
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1597883495
- Cited by
- 70
- References
- 16
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Zolpidem in the Management of Insomnia. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00158.x
- The paper
- Dang, A., Garg, A., & Rataboli, P. V. (2011). Role of Zolpidem in the Management of Insomnia. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00158.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.